There are protein transcription factors, and now siRNA-mediated gene silencing.
http://www.newswire.ca/releases/October2002/02/c6803.html
QIAGEN launches first Cancer siRNA Oligo Set
VENLO, the Netherlands, Oct. 2 /CNW/ - QIAGEN N.V. (Nasdaq: QGENF,
Frankfurt, Neuer Markt: QIA) today announced the launch of the Cancer siRNA
Oligo Set, the first set of disease-specific siRNAs for the life sciences
market. This product launch positions QIAGEN as the world market and
technology leader for products and services focused on siRNA-mediated gene
silencing.
This powerful discovery tool is comprised of two siRNAs for each of 139
cancer-related genes, which are recognized as clinically and scientifically
relevant. Every siRNA has been designed using state-of-the-art design criteria
to maximize gene-silencing potential, and has been synthesized using QIAGEN's
patented TOM-amidite chemistry to yield high-quality, high-purity RNA
oligonucleotides. QIAGEN's siRNA products combine with QIAGEN's RNA
transfection technologies to provide a fully integrated solution for gene
silencing.
QIAGEN's proprietary synthetic siRNA synthesis technologies address one
of the most dynamic areas of today's functional genomics market. The ability
to simply, effectively and specifically down-regulate the expression of genes
in mammalian cells holds enormous scientific, commercial, and therapeutic
potential.
"We are very proud here at QIAGEN to introduce the first disease-specific
siRNA set. Being at the forefront of this technology as a leader gives us the
competitive advantage of being the first mover in the market. The depth,
significance, and rapid development of this new technology is creating a high
degree of excitement throughout the scientific community, and the ability to
perform large scale exploratory screening of cancer related genes takes us one
step further to understanding the complex mechanisms of cancer" said Patrick
Weiss, Director of Gene Silencing, and founder of Xeragon Inc., which was
recently acquired by QIAGEN.
About QIAGEN
QIAGEN N.V., a Netherlands holding company with subsidiaries in Germany,
the United States, Japan, the United Kingdom, Switzerland, France, Italy,
Australia, Norway, Austria and Canada, believes it is the world's leading
provider of innovative enabling technologies and products for the separation,
purification and handling of nucleic acids. The Company has developed a
comprehensive portfolio of more than 320 proprietary, consumable products for
nucleic acid separation, purification and handling, nucleic acid
amplification, as well as automated instrumentation, synthetic nucleic acid
products and related services. QIAGEN's products are sold in more than 42
countries throughout the world to academic research markets and to leading
pharmaceutical and biotechnology companies. In addition, the Company is
positioning its products for sale into developing commercial markets,
including DNA sequencing and genomics, nucleic acid-based molecular
diagnostics, and genetic vaccination and gene therapy. QIAGEN employs
approximately 1,700 people worldwide. Further information on QIAGEN can be
found at www.qiagen.com. |
